In complex clinical trials, packaging and labelling are often treated as necessary executional steps — but secondary.
In reality, they are critical control points. Errors in packaging do not remain isolated. They can delay site activation, trigger rework, create regulatory exposure, and ultimately disrupt patient continuity.
This case study explores how BAP Pharma supported a sponsor in managing packaging risk within a multi-country Phase III trial — ensuring control, compliance, and continuity under pressure.
The Challenge
A mid-sized biotech sponsor was preparing a Phase III oncology study across six European markets.
The trial required multi-language labelling aligned to local regulatory requirements, blinded packaging with strict protocol adherence, and rapid timelines to meet site activation milestones. As the study progressed, risk began to build.
Late-stage protocol amendments introduced ongoing changes to labelling requirements. At the same time, increasing translation complexity created additional pressure on regulatory alignment, while compressed timelines heightened the risk of version control errors.
These were not theoretical concerns, they represented real operational and regulatory exposure. Even a minor packaging discrepancy could delay site activation, trigger relabelling campaigns, increase regulatory scrutiny, or disrupt patient dosing.
The sponsor needed a partner who could reduce risk without slowing delivery or increasing operational complexity.
The BAP Pharma Approach
BAP approached the engagement not as a packaging task, but as a risk management and control exercise.
Rather than reacting to issues as they emerged, the focus was on designing a process that would prevent them from occurring in the first place.
Structured Control and Version Management
Clear version control protocols were implemented to ensure that all artwork and labelling updates were aligned to the latest approved protocol.
Proactive Change Management
Recognising that further protocol amendments were likely, BAP designed a packaging process that could absorb change without disrupting delivery timelines.
Coordinated multi-country execution
Translation, regulatory interpretation, and country-specific requirements were centrally coordinated to ensure consistency across all six markets — reducing the likelihood of discrepancies that could trigger delays or compliance issues.
Alignment across stakeholders
Regular checkpoints across Clinical Supply, QA, and Regulatory teams ensured decisions were made quickly, ownership remained clear, and miscommunication was minimised.
Quality built in — not inspected at the end
Rather than relying on final-stage checks, quality assurance was embedded throughout the process, significantly reducing the risk of rework or late-stage intervention.
In complex trials, packaging risk is rarely about a single error — it’s about control. If version management isn’t rigorous, issues can escalate very quickly.
Change is inevitable in clinical trials. The key is not reacting to it but designing processes that can handle it without introducing risk.
The Outcome
The packaging and labelling programme was delivered right first time, with no rework required.
All materials were released on schedule, enabling site activation as planned. The programme remained fully compliant, with no audit or inspection findings, and full traceability was maintained across all markets.
Most importantly, the trial progressed without disruption — protecting both timelines and patient continuity.
Key Insight
Packaging errors rarely occur in isolation. They are typically the result of weak control structures, reactive change management, fragmented ownership, and insufficient early-stage planning.
When packaging is treated as a governed, controlled process, it shifts from execution to risk management.
Risk is anticipated and designed out, not reacted to under pressure.
Why It Matters
In multi-country clinical trials, packaging is not simply a production step. It is a compliance-critical control point within the trial supply chain. Getting it right ensures:
- Trial continuity
- Regulatory confidence
- Reduced operational risk
- Protection of patient outcomes
BAP Pharma Perspective
At BAP Pharma, packaging and labelling are approached as part of a broader commitment to certainty, compliance, and continuity.
Because in clinical trials, precision is not optional, it is essential.
Packaging sits at the intersection of operational execution and regulatory compliance. Getting it right requires both precision and foresight.
The difference between a smooth trial and a disrupted one is often not the complexity, it’s how well that complexity is managed.
